Skip to main content

Table 2 Cost inputs

From: Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer

Country/costs (USD)

Trastuzumab treatment

Local recurrence

Distance recurrence

Congo

20,000

974

1356

Ethiopia

20,000

1323

1841

Guinea

20,000

1136

1581

Kenya

20,000

2769

3853

Namibia

20,000

9719

13,524

Nigeria

20,000

5446

7578

Rwanda

20,000

1456

2027

Uganda

20,000

1424

1981

Zambia

20,000

2695

3751

Zimbabwe

20,000

2090

2909

South Africa

20,000

11,836

16,470